Atsakinga medicina - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 19,638 | 56,440 | 43,842 | 56,880 | 43,014 | 45,132 | 50,175 | 39,419 |
| Profit before tax | -23,481 | 3,030 | 344 | 7,686 | 2,386 | 12,543 | 25,641 | 26,317 |
| Net profit | -23,481 | 2,985 | 339 | 7,571 | 2,350 | 12,355 | 25,256 | 25,385 |
| Equity | 7,392 | 10,377 | 10,716 | 18,287 | 20,637 | 32,992 | 58,248 | 83,633 |
| Liabilities | 254,509 | 208,143 | 195,287 | 180,635 | 149,517 | 125,095 | 90,134 | 52,097 |
| Non-current assets | 211,318 | 184,541 | 158,319 | 135,949 | 126,210 | 108,933 | 98,841 | 86,035 |
| Current assets | 50,583 | 33,979 | 47,684 | 62,973 | 43,944 | 49,154 | 49,541 | 49,695 |
| Total assets | 261,901 | 218,520 | 206,003 | 198,922 | 170,154 | 158,087 | 148,382 | 135,730 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 7,713 | 1,381 | 11,414 |
| Social insurance contributions | - | - | - | - | - | 2,051 | - | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | +256.8% | +187.4% | -22.3% | +29.7% | -24.4% | +4.9% | +11.2% | -21.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -9.0% | 1.4% | 0.2% | 3.8% | 1.4% | 7.8% | 17.0% | 18.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -317.7% | 28.8% | 3.2% | 41.4% | 11.4% | 37.4% | 43.4% | 30.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -119.6% | 5.3% | 0.8% | 13.3% | 5.5% | 27.4% | 50.3% | 64.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -119.6% | 5.4% | 0.8% | 13.5% | 5.5% | 27.8% | 51.1% | 66.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 34.4 | 20.1 | 18.2 | 9.9 | 7.2 | 3.8 | 1.5 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 4,208 | 11,288 | 11,691 | 11,009 | 10,121 | 9,026 | 16,725 | 13,140 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Atsakinga medicina - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-09-16 | 2025-09-24 | 84.04 |
| 2024-08-19 | 2024-08-26 | 248.81 |
| 2024-02-19 | 2024-02-19 | 221.01 |
| 2023-09-18 | 2023-09-21 | 115.09 |
| 2023-08-17 | 2023-08-20 | 217.67 |
| 2023-03-16 | 2023-03-19 | 143.60 |
| 2022-10-28 | 2022-11-10 | 0.18 |
| 2022-10-18 | 2022-10-27 | 394.70 |
| 2022-09-16 | 2022-09-18 | 151.13 |
| 2022-01-18 | 2022-01-19 | 436.12 |
Atsakinga medicina - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-01 | 2026-04-08 | 453.83 |
| 2026-03-29 | 2026-03-31 | 453.39 |
| 2026-03-27 | 2026-03-28 | 452.4 |
| 2026-03-20 | 2026-03-26 | 633.99 |
| 2026-03-19 | 2026-03-19 | 452.4 |
| 2026-01-29 | 2026-02-16 | 0.01 |
| 2026-01-01 | 2026-01-03 | 434.45 |
| 2025-11-28 | 2025-12-31 | 0.23 |
| 2025-11-15 | 2025-11-22 | 0.23 |
| 2025-10-30 | 2025-11-14 | 0.29 |
| 2025-09-30 | 2025-10-20 | 0.29 |
| 2025-09-28 | 2025-09-29 | 433.85 |
| 2025-06-28 | 2025-06-30 | 221.37 |
| 2025-03-31 | 2025-03-31 | 4104.74 |
| 2025-03-29 | 2025-03-30 | 3897.09 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Atsakinga medicina, UAB (code 304166823) is a Private Limited Liability Company engaged in general medical practice activities. In 2025, revenue declined to €39.4K from €50.2K in 2024 and €45.1K in 2023, indicating a weaker sales trend and a 21.4% year-on-year decrease. Even so, net profit remained stable at €25.4K in 2025, compared with €25.3K in 2024 and €12.4K in 2023, supported by higher operating efficiency. Profit margin improved to 64.4% in 2025, following 50.3% in 2024 and 27.4% in 2023. Equity strengthened to €83.6K at the end of 2025 from €58.2K a year earlier and €33.0K in 2023, while liabilities fell to €52.1K from €90.1K and €125.1K. Total assets stood at €135.7K in 2025, down from €148.4K in 2024. The balance sheet was composed of €86.0K in long-term assets and €49.7K in short-term assets. Latest ratios show ROE of 30.4%, ROA of 18.7%, debt-to-equity of 0.62, and asset turnover of 0.29x. Revenue per employee was €13.1K.